Explore

TrendlineTrendline
Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials
TrendlineTrendline
ADC Therapeutics Reports Increased Product Revenue and Strategic Financial Restructuring in Q3 2026

ADC Therapeutics Reports Increased Product Revenue and Strategic Financial Restructuring in Q3 2026

ADC Therapeutics Reports Increased Product Revenue and Strategic Financial Restructuring in Q3 2026
TrendlineTrendline
Senseonics Holdings Hits 52-Week High Following Q3 Beat and Raymond James Upgrade

Senseonics Holdings Hits 52-Week High Following Q3 Beat and Raymond James Upgrade

Senseonics Holdings Hits 52-Week High Following Q3 Beat and Raymond James Upgrade
TrendlineTrendline
ADC Therapeutics Reports Strong Q3 2026 Financial Results and Strategic Restructuring

ADC Therapeutics Reports Strong Q3 2026 Financial Results and Strategic Restructuring

ADC Therapeutics Reports Strong Q3 2026 Financial Results and Strategic Restructuring
TrendlineTrendline
Vir Biotechnology Stock Surges Over 10% Following Positive Hepatitis Delta Trial Results

Vir Biotechnology Stock Surges Over 10% Following Positive Hepatitis Delta Trial Results

Vir Biotechnology Stock Surges Over 10% Following Positive Hepatitis Delta Trial Results
TrendlineTrendline
KeyCorp's Michael Leshock Downgrades Rocket Lab Stock Target Amid Neutron Delay

KeyCorp's Michael Leshock Downgrades Rocket Lab Stock Target Amid Neutron Delay

KeyCorp's Michael Leshock Downgrades Rocket Lab Stock Target Amid Neutron Delay
TrendlineTrendline
Public Storage Files Prospectus for Resale of Up to 120,011 Shares

Public Storage Files Prospectus for Resale of Up to 120,011 Shares

Public Storage Files Prospectus for Resale of Up to 120,011 Shares
TrendlineTrendline
Infinity Natural Resources Reports Strong Q3 2026 Results and Narrows Full-Year Guidance

Infinity Natural Resources Reports Strong Q3 2026 Results and Narrows Full-Year Guidance

Infinity Natural Resources Reports Strong Q3 2026 Results and Narrows Full-Year Guidance
TrendlineTrendline
Tonix Pharmaceuticals Anticipates Q3 2026 Financial Results, Analysts Project Loss Amid Revenue Growth

Tonix Pharmaceuticals Anticipates Q3 2026 Financial Results, Analysts Project Loss Amid Revenue Growth

Tonix Pharmaceuticals Anticipates Q3 2026 Financial Results, Analysts Project Loss Amid Revenue Growth
TrendlineTrendline
Veeva Systems Hosts Analyst/Investor Day, Outlines Future Strategies

Veeva Systems Hosts Analyst/Investor Day, Outlines Future Strategies

Veeva Systems Hosts Analyst/Investor Day, Outlines Future Strategies
ReutersReuters
Anthropic's $1.4 trillion IPO bid sets up high-stakes test for AI market

Anthropic's $1.4 trillion IPO bid sets up high-stakes test for AI market

Nov 10 (Reuters) - Anthropic's blockbuster IPO is set to give the company a valuation of up to $1.4 trillion, marking a defining test of investor confidence in the AI boom it helped ignite.
ReutersReuters
Anthropic targets $1 trillion IPO valuation in key test for AI market

Anthropic targets $1 trillion IPO valuation in key test for AI market

Nov 10 (Reuters) - Anthropic's IPO plans to raise as much as $64.4 billion, a regulatory filing showed on Tuesday, testing Wall Street's faith in the AI boom amid growing worries about its risks.